A Test for Multiple Binary Endpoints with Continuous Latent Distribution in Clinical Trials

被引:0
|
作者
Takuma Ishihara
Kouji Yamamoto
机构
[1] Gifu University Hospital,Innovative and Clinical Research Promotion Center
[2] Yokohama City University School of Medicine,Department of Biostatistics
关键词
Latent variable; Non-inferiority; Superiority;
D O I
暂无
中图分类号
学科分类号
摘要
In clinical trials, two or more binary responses obtained by dichotomizing continuous responses are often employed as multiple primary endpoints. Testing procedures for multiple binary variables with latent distribution have not yet been adequately discussed. Based on the association measure among latent variables, we provide a statistic for testing the superiority of at least one binary endpoint. In addition, we propose a testing procedure with a framework in which the trial efficacy is confirmed only when there is superiority of at least one endpoint and non-inferiority of the remaining endpoints. The performance of the proposed procedure is evaluated through simulations.
引用
收藏
页码:463 / 480
页数:17
相关论文
共 50 条
  • [31] Recurrent disability progression endpoints in multiple sclerosis clinical trials
    Buehler, Alexandra
    Wolbers, Marcel
    Model, Fabian
    Wang, Qing
    Belachew, Shibeshih
    Manfrini, Marianna
    Lorscheider, Johannes
    Kappos, Ludwig
    Beyersmann, Jan
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (01) : 130 - 139
  • [32] Recommendations for including multiple symptoms as endpoints in cancer clinical trials
    Cleeland, Charles S.
    Sloan, Jeff A.
    Cella, David
    Chen, Connie
    Dueck, Amylou C.
    Janjan, Nora A.
    Liepa, Astra M.
    Mallick, Rajiv
    O'Mara, Ann
    Pearson, Jay D.
    Torigoe, Yasuhiro
    Wang, Xin Shelley
    Williams, Loretta A.
    Woodruff, Jeanie F.
    CANCER, 2013, 119 (02) : 411 - 420
  • [33] Inference on multiple endpoints in clinical trials with adaptive interim analyses
    Kieser, M
    Bauer, P
    Lehmacher, W
    BIOMETRICAL JOURNAL, 1999, 41 (03) : 261 - 277
  • [34] THE USE OF RANDOMIZATION TESTS FOR MULTIPLE ENDPOINTS IN CLINICAL-TRIALS
    KARRISON, T
    CONTROLLED CLINICAL TRIALS, 1985, 6 (03): : 240 - 241
  • [35] Some remaining challenges regarding multiple endpoints in clinical trials
    Snapinn, Steven
    STATISTICS IN MEDICINE, 2017, 36 (28) : 4441 - 4445
  • [36] DESIGN OF GROUP SEQUENTIAL CLINICAL-TRIALS WITH MULTIPLE ENDPOINTS
    TANG, DI
    GNECCO, C
    GELLER, NL
    JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1989, 84 (407) : 776 - 779
  • [37] Reducing unnecessary measurements in clinical trials with multiple primary endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (04) : 631 - 643
  • [38] One-sided tests in clinical trials with multiple endpoints
    Bloch, DA
    Lai, TL
    Tubert-Bitter, P
    BIOMETRICS, 2001, 57 (04) : 1039 - 1047
  • [39] Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan
    Sakamaki, Kentaro
    Yoshida, Seitaro
    Morita, Yusuke
    Kamiura, Toshifumi
    Iba, Katsuhiro
    Ogawa, Naoyuki
    Suganami, Hideki
    Tsuchiya, Satoru
    Fukimbara, Satoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (03) : 528 - 533
  • [40] Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan
    Kentaro Sakamaki
    Seitaro Yoshida
    Yusuke Morita
    Toshifumi Kamiura
    Katsuhiro Iba
    Naoyuki Ogawa
    Hideki Suganami
    Satoru Tsuchiya
    Satoru Fukimbara
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 528 - 533